A Dividend ETF's Earnings Marathon: Chevron, Shell and AbbVie Put a €8.9 Billion Fund to the Test
Published on 07/31/2026 at 14:11 | Redaktion boerse-global.de
The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF has spent the past week riding a wave of blockbuster earnings from its heaviest hitters — and the results are a masterclass in how concentrated dividend strategies can be. After touching a fresh 52-week high of €55.50 on Wednesday, the fund slipped 0.45% to €55.09, a modest pullback that belies the intensity of the reporting season unfolding beneath the surface.
Shell's Comeback Quarter Sets the Tone
The rally began in earnest on July 30, when Shell delivered what it called its strongest quarterly performance since 2022. The Anglo-Dutch major posted adjusted earnings of $9.8 billion for the second quarter of 2026 — the best figure since the $11.47 billion it banked in Q2 2022, when Russia's invasion of Ukraine sent energy prices soaring. CEO Wael Sawan credited favorable market conditions but insisted operational execution was the real driver. "Volatility is the new normal," he told CNBC, arguing Shell had prepared specifically for such turbulent phases.
The operational metrics back that claim. Despite outages in the Middle East, Shell achieved record production in Brazil and record refinery utilization. Operating cash flow reached $21.4 billion, and the company announced its 19th consecutive quarterly buyback of at least $3 billion, alongside a fresh interim dividend. London-listed Shell shares rose 1.5% on the day, though the stock's year-to-date gain of roughly 21% still trails rivals like BP, TotalEnergies, Exxon Mobil and Chevron.
Chevron Follows Suit
Just days later, Chevron added its own headline numbers. The U.S. supermajor reported second-quarter net income of $12.1 billion, with adjusted earnings per share of $6.06 comfortably beating the $5.80 consensus. Revenue surged to $70.06 billion against analyst expectations of just $57.53 billion, fueled by record U.S. production of 2.08 million barrels of oil equivalent per day. Global output rose 20% year over year.
The two energy giants weren't alone in impressing. Shell and TotalEnergies — both top-ten holdings in the fund — had already posted similarly strong results, setting the stage for a reporting season that has validated the fund's structural bet on high-yielding sectors.
AbbVie's Friday Test
Friday morning brought the third major test: AbbVie's quarterly report, released before U.S. markets opened. The market was looking for earnings of $3.66 per share on revenue of roughly $16.81 billion. Analysts had flagged that the pharma giant's growth increasingly hinges on its immunology franchise — specifically Skyrizi and Rinvoq — as Humira's patent protection continues to erode.
For the ETF, AbbVie's numbers carry outsized weight. Healthcare ranks among the fund's largest sector exposures alongside financials and energy. Whether pharmaceutical names like AbbVie can sustain their payout ratios is a core condition for remaining in the underlying Morningstar index — a screening process that demands dividends never decline over five years and payout ratios stay below 75%.
A Fund Built on Dividends, Not Market Caps
The fund's sensitivity to individual earnings reports is by design. Unlike market-cap-weighted indices, the Morningstar Developed Markets Large Cap Dividend Leaders Index weights constituents by total dividends paid. That tilts the portfolio heavily toward energy, financials and healthcare — sectors that historically dominate the top of the dividend leaderboard.
Shell, Exxon Mobil, Verizon, Nestlé, Pfizer and TotalEnergies all sit among the top ten holdings, alongside PepsiCo, Allianz, Novo Nordisk and Intesa Sanpaolo. Together, the top ten account for more than a third of the portfolio. A strong quarter from an oil major like Shell or TotalEnergies therefore moves the needle far more than it would in a conventional global index fund.
Technical Signals Flash While Fundamentals Hold
The fund's momentum is undeniable but increasingly stretched. At €55.09, it trades well above its 50-day average of €52.84 and its 200-day average of €50.48. The relative strength index stood at 68.2 in the primary article's data — though the secondary source put it at 72.9, a level that typically signals overbought conditions. Either reading suggests the rally is running hot, and the secondary source's higher figure points to a potential short-term pullback risk.
Performance tells a similar story of strength. Year-to-date gains stand at 14.68% (or 15.20% depending on the measurement date), while the twelve-month return ranges from 27.86% to 28.44% — comfortably outpacing most broad market benchmarks.
German Trading Desks Show Appetite for Yield
The fund's appeal has been particularly visible on German trading floors. Through the final week of July, Frankfurt saw a clear demand surplus for the ETF, even as technology-heavy funds came under selling pressure amid valuation concerns. Dividend-oriented value strategies remained in favor, a rotation that has helped the fund swell to roughly €8.9 billion in assets under management.
The fund uses full physical replication to track its benchmark, distributing quarterly. Its fortunes are thus tied directly to the cash-generating power of a relatively small group of large dividend payers — a dependency that Shell's record quarter and Chevron's blowout numbers have made abundantly clear. With AbbVie's report now out and the earnings season rolling on, the next few weeks will test whether the fund's fundamental tailwinds can outrun its technical warnings.
Ad
VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock: New Analysis - 31 July
Fresh VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF analysis...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
